Articles Tagged With: Medication
-
Mefloquine: Still Effective and Still Safe for Malaria Chemoprophylaxis
Mefloquine is known as an effective agent for malaria chemoprophylaxis. However, concerns about serious adverse effects have limited its use. Now, a careful review of data suggests that fatal outcomes related to mefloquine prophylaxis are very rare.
-
A Novel Approach to Using Mind-Body Therapies for Chronic Pain
Chronic pain is a multifactorial public health issue and the treatment plan needs to address all biopsychosocial aspects of this disease.
-
HIV Pre-exposure Prophylaxis for Adolescents: A Health Equity and Reproductive Justice Issue
Access to HIV pre-exposure prophylaxis is not just a public health issue, but equally important, an equity and justice issue.
-
Can College Health Centers Improve Access to Abortion Care?
College health centers may be a student’s only access to healthcare, especially on campuses in rural areas.
-
Pharmacologic Management of Type 2 Diabetes Mellitus: Part 2
This two-part series of articles will address pharmacological agents, except insulin, used to manage type 2 diabetes mellitus. Part 1 covered sodium glucose co-transporter-2 inhibitors, incretin-based therapies, amylin analog, and dopamine receptor agonists. Part 2 will focus on biguanides, thiazolidinediones, sulfonylureas, meglitinides, alpha-glucosidase inhibitors, and bile acid resins, as well as the authors’ treatment recommendations. Appendix A (http://bit.ly/2eyB4Px) is a comprehensive table of the effectiveness and costs of various combination therapies.
-
Kaiser Accused of Shorting Meds to Save Money
An anesthesiologist is suing Kaiser Permanente for $9 million, claiming that he was fired for complaining when told to reduce patient medications so they could be discharged sooner.
-
Wrong-patient Errors Can Lead to Death, But They Can Be Prevented
About 9% of the wrong-patient events studied for a just-released report led to temporary or permanent harm or, in some cases, death.
-
Managing Type 2 Diabetes Mellitus: Part 1
MONOGRAPH: Covering sodium glucose co-transporter-2 inhibitors, incretin-based therapies, amylin analog, and dopamine receptor agonists.
-
Excessive Prescriptions Result in $17.6M Award In Compensatory and Punitive Damages
In 2008, a 45-year-old man’s primary care physician began prescribing powerful and highly addictive pain pills for lower-back pain. The pain pills, known as opioids, are prescribed at alarming levels for millions of patients in the United States, which results in frequent addiction and serious side effects.
-
FDA Updates Mifepristone Labeling, Easing Access to Abortion Pill
The Food and Drug Administration has approved new and updated labeling for the medication abortion drug mifepristone (Mifeprex, Danco Laboratories, New York City) to reflect the most current clinical practices and safety and efficacy data. The drug’s new label reduces the size of the initial dose and extends the window for taking it to 70 days since the first day of a woman’s last menstrual period.